US-based molecular diagnostics company Myriad Genetics has acquired breast cancer prognostic company, Sividon Diagnostics in a deal valued at €50m.
The transaction was done for €35m with a potential additional investment of €15m conditioned on achieving performance-based milestones.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Myriad is planning to fund the transaction on an all-cash basis and expects that the transaction will cast no effect on the company’s revenue and earnings in fiscal year 2017.
The transaction has added to Myriad’s portfolio of oncological devices, such as Sividon’s EndoPredict test which is a kit-based RNA expression test measuring the gravity of breast cancer on a molecular level and assists the patients to decide whether to avoid chemotherapy.
Myriad is planning to integrate the product on their Thermo Fisher QuantStudio platform which is currently CE Marked on the Siemens Versant instrument.
Myriad Genetic Laboratories president and CEO Mark Capone said: "The EndoPredict test will be the foundational product of our newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide."
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe company seeks to increase the market footprint of EndoPredict which they project is greater than $600m with its majority existing in European countries, Canada, and the US.
About 4,000 patients have been subjected to the EndoPredict test and used by more than 13,000 patients exhibiting the product’s ability to determine which patients are at low risk for distant metastases in both node negative and node positive patients.
